Clinical trial
Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects
NCT00244751 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00244751 |
|---|---|
| Title | Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cirrhosis, Liver |
| Intervention type | Drug |
| Interventions | GI262570 0.5 mg, GI262570 1.0 mg, Placebo |
| Enrollment | 265 |
| Start date | Nov 2, 2005 |
| Primary completion | Mar 13, 2008 |
| Completion | Mar 13, 2008 |
| First posted | Oct 27, 2005 |
| Last update posted | Dec 11, 2017 |
| Countries | Australia, Canada, Czechia, Germany, Israel, Malaysia, New Zealand, Puerto Rico, Romania, Russia, Singapore, South Korea and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: